MyVisionTest News Archive

Displaying news items tagged with adverse drug effects (More tags »)
SELECT PAGE
First <<  1 2 3 4   >> Last

CATT trial logo
Jan 15, 2012
The long-awaited primary outcome of the Comparison of Age-related Macular Degeneration Treatments Trial (CATT) study was that patients receiving either monthly Avastin (bevacizumab) or monthly Lucentis (ranibizumab) had equivalent visual acuity at 1 year. For the majority of clinicians who already preferentially used Avastin for age-related...

Full Article


CATT trial logo
Jan 15, 2012
The much anticipated CATT study has now been published. The National Eye Institute is to be applauded for having sponsored this landmark trial and for setting a new standard of transparency by submitting most of the raw data on the Internet. Millions of people who cannot afford Lucentis (ranibizumab) now have the benefit of a high level of...

Full Article


Avastin
Jan 14, 2012
The authors report a cluster of 14 consecutive cases of sterile endophthalmitis occurred after intravitreal injection of Avastin (bevacizumab) obtained from a single batch that occured in Japan circa 2009. Intravitreous Avastin (IVB) can cause complications, including traumatic cataract, retinal detachment, and endophthalmitis, with the...

Full Article


Intravitreal injection
Jan 14, 2012
Elevated intraocular pressure (IOP) after an intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents for age-related macular degeneration (AMD) is not uncommon, but this study failed to identify any significant risk factors for its occurrence. Studies investigating transient increases in intraocular pressure (IOP)...

Full Article


Intraocular pressure
Jan 14, 2012
Neovascular age-related macular degeneration (AMD) patients undergoing unilateral intravitreal Lucentis (ranibizumab) and/or Avastin (bevacizumab) injections are more likely to suffer intraocular pressure (IOP) elevation of at least 5 mmHg of 2 or more visits if they recieve a greater number of injections, according to a new study. Intravitreal...

Full Article


Avastin
Jan 14, 2012
Intraocular injections of anti–vascular endothelial growth factor (VEGF) agents have yielded dramatic improvements in the management of a wide variety of neovascular ocular diseases including age-related macular degeneration (AMD), diabetic retinopathy (DR), retinal vein occlusion, and retinopathy of prematurity. These agents have thus become...

Full Article


Uveitis
Jan 14, 2012
Anti–vascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (AMD) is associated with increased risk of endophthalmitis, uveitis, and vitreous hemorrhage, according to a recent study. Since 2005, the advent and widespread use of anti–vascular endothelial growth factor (VEGF) drugs for the...

Full Article


Avastin
Jan 7, 2012
Health Canada is warning the public and doctors about cases of blindness in the U.S. that have been linked to off-label use of the drug Avastin. Three clusters of cases of serious complications including blindness have been reported in the United States after the drug was used to treat macular degeneration, the department said in a statement in...

Full Article


cardiovascular system
Mar 9, 2011
Researchers found that the incidence of arterial thromboembolic events (ATEs, "blood clots") in patients treated with Avastin (bevacizumab) was significantly higher than patients treated with Lucentis (ranibizumab) for exudative age-related macular degeneration (AMD). Lucentis has revolutionized the treatment of age-related macular...

Full Article


Intravitreal injection
Mar 8, 2011
To evaluate the amount of reflux and degree of pain with intravitreal injection (IVT) using 6 different types of syringes/needles and 5 techniques of scleral incision, including 3 modifications of a beveled scleral incision. The risk of serious adverse events reported after intravitreal (IVT) injection injection is low. Endophthalmitis, which...

Full Article


SELECT PAGE
First <<  1 2 3 4   >> Last
Most Popular
Less - past - More